RegulatoryCompany release

FDA grants priority review to Belite Bio's tinlarebant for Stargardt disease; PDUFA date 12 February 2027

Belite Bio, Inc (BLTE) · Thu 12 Nov 2026

Belite Bio says the FDA will not convene an advisory committee for its Stargardt disease type 1 application, as filings also proceed in Japan and through the Access Consortium.

Belite Bio has said the US Food and Drug Administration accepted its new drug application for tinlarebant in Stargardt disease type 1 (STGD1) with priority review in August 2026. The agency has set a PDUFA goal date of 12 February 2027, according to the company's third-quarter 2026 update.

The company also said the FDA does not plan to hold an advisory committee meeting for the application. Priority review is a designation that shortens the agency's target review timeline compared with a standard review.

Outside the US, Belite Bio has filed for approval in Japan, where the product holds Sakigake designation, with the submission made in September 2026. In October 2026 it filed in Singapore, the UK and Switzerland through the Access Consortium, a work-sharing arrangement among regulators.

On finances, the company reported $271.3 million in cash and $502.7 million in US Treasury holdings as of 30 September 2026.

What it means for your team

  • The 12 February 2027 PDUFA date gives a fixed milestone for tracking a potential first-in-class decision in STGD1.
  • The absence of an advisory committee means no public panel discussion of the data before the FDA's action.
  • Parallel filings in Japan and via the Access Consortium (Singapore, UK, Switzerland) point to near-simultaneous review timelines across several regions.
  • Teams planning for launch or market access should note the company's reported cash and Treasury holdings as stated in its update.

Company's press release (SEC filing): Belite Bio, Inc ↗

Article written by VigiEye from the official source (Belite Bio, Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →